Technology evaluation: Fomivirsen, Isis Pharmaceuticals Inc/CIBA Vision

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 3, 2001, Pages 288-294

  Orr, R M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; CIDOFOVIR; CORTICOSTEROID; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GENE EXPRESSION MODULATOR 231; MG 98; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG APPROVAL; DRUG COST; DRUG DISTRIBUTION; DRUG MARKETING; DRUG METABOLISM; EUROPE; EVALUATION; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY GENE; LIVER TOXICITY; NONHUMAN; RAT; RETINA MACULOPATHY; RETINITIS; SUMMER; TECHNOLOGY; THROMBOCYTOPENIA; UVEITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; HUMANS; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

EID: 0034945407     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Isis begins phase III clinical trials of antisense compound to treat retinitis in patients with AIDS
2. Isis' CMV retinitis phase III trial
3. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
4. Human Genome Sciences and Isis Pharmaceuticals form antisense collaboration
5. Prospects for antisense therapy are looking brighter
6. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
7. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs
8. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
9. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides
10. Phosphorothioate oligodeoxynucleotides - Antisense inhibitors of gene expression?
11. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element
12. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015
13. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit
14. Therapeutic options for resistant cytomegalovirus retinitis
15. DepoTech Corp - Corporate profile 1997
16. Isis and CIBA Vision will present phase III results for CMV retinitis drug at ICAR meeting, April 5th
17. Isis and CIBA Vision submit New Drug Application to the FDA for CMV retinitis drug/First NDA for an antisense drug; filing triggers significant milestone payment
18. Isis files 1st NDA for antisense drug
19. Isis and CIBA Vision announce European regulatory filing for CMV retinitis drug
20. FDA panel backs approval of Isis' first antisense drug
21. FDA approves Isis' Vitravene
22. Isis achieves $7.5 million milestone for FDA approval of antisense CMV retinitis drug European regulatory application undergoing review
23. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
24. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
25. CIBA Vision launches Vitravene, novel antisense mechanism drug for treatment of CMV retinitis
26. Seeking partnering opportunities in Japan: Dr Anderson of Isis pharmaceuticals
27. Antisense oligonucleotides: Novel therapeutics for viral disease
28. Antisense oligonucleotides: Is the glass half full or half empty
29. European approval of Vitravene triggers $2.5 MM milestone for Isis
30. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer
31. Isis announces completion of $7.5 million financing with Elan
32. Patent review: Therapeutic applications for antisense oligonucleotides 1999-2000
33. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
34. Isis Pharmaceuticals Inc: Isis Pharmaceuticals' GeneTrove division demonstrates crucial role of PTEN gene in Type II diabetes; PTEN validated as a novel therapeutic target for diabetes
35. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
36. Fomivirsen
37. Disposition and toxicity of a mixed backbone antisense oligonucleotide, targeted against human cytomegalovirus, after intravitreal injection of escalating doses in the rabbit
38. Vitravene
39. Johns Hopkins AIDS Service Publications: Medical management of HIV infection. Charter 6: Formivirsen
40. Antisense: Poised to strike
41. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance
42. First antisense compound clears US regulatory hurdle
43. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis
44. Isis Pharmaceuticals' TNF-α inhibitor, ISIS 104838, enters phase I human clinical trials for the treatment of rheumatoid arthritis and Crohn's disease
45. Progress in antisense technology: The end of the beginning
46. Mechanisms of action of antisense oligonucleotides
47. A phase I and pharmacokinetic (PK) study of MG98, a human DNA methyltransferase (MeTase) antisense oligonucleotide, given as a P-hour twice weekly (BIW) infusion 3 out of every 4 wks
48. Phase I and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, administered as 21-day infusion q4 weekly